Attendee search 

Olympus was founded in 1919 and launched our first gastro-camera in the 1950s. Since then, Olympus developed into a MedTech leader, designing and delivering innovative solutions for medical and surgical procedures, especially in the field of endoscopy.

We are Petrone Group Asia Pacific , a Petrone Group ( www.petrone.it ) sister company dedicated to Global Comparators sourcing for clinical trials to China and APAC region.

We give support to Sponsors , CROs , Clinical Research Institutes , Pharma and Biotech company for IMP management and Comparators sourcing.

Our service has high flexibility in managing clinical trials from phase I to phase IV according to customers’ specific requirements.

To have a better idea of our Global sourcing capabilities please find below a recap of Petrone Group Headquarters and branches

HQ Italy
Euromed , Italian comparator drugs

EU Branches
BCN FARMA Spain / Spanish comparator drugs
PHD Pharmaceuticals / Irish and EU comparator drugs

US Branch
Euromed Pharma NY / US and Canada comparator drugs

Asia Pacific Branch
Petrone Group Asia Pacific Singapore / Asia Pacific and Australia comparator drugs

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

Santen Pharmaceutical Co., Ltd. (参天製薬株式会社), is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.

We are looking for investment and licensing opportunites in the ophthalmology field. 

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Eczema, Acne, Rosacea.
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.

LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.

LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.

iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.